Abstract
Amiodarone (AMD) is an antiarrhythmic drug which contains 37% of iodine. It can reach the fetus by transplacental passage and induce fetal hypothyroidism. Since in some pregnant women AMD represents a cardinal therapeutic opportunity, it is necessary to establish not only the risk of teratogenicity linked to fetal AMD exposure but also to evaluate the psychomotor development of children with neonatal thyroid dysfunction related to fetal AMD exposure. We report on two cases involving children with an AMD gestational exposure and transient neonatal hypothyroidism, who were followed-up until the age of 4 years 8 months and 5 years 6 months, respectively. Denver’s developmental milestone test and Whechsler Preschool and Primary Scale of Intelligence (WPPSI) were administered to the patients in accordance to their age. A normal psychomotor development was observed in both patients with full scale IQ score, verbal and performance IQ scores within normal range. In conclusion, if these data were validated by larger studies, it might not be obligatory to discontinue AMD administration in cardiopathic pregnant women, since mental impairment may not necessarily occur in children with transient neonatal hypothyroidism caused by fetal AMD exposure. However, the evaluation of the thyroid function of these children is imperative.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Caron P. Effets de l’Amiodarone sur la fonction thyroïdienne. Presse Med. 24: 1747, 1995.
Martino E., Aghini-Lombardi F., Mariotti S., Bartalena L., Braverman L.E., Pinchera A. Amiodarone: a common source of iodine-induced thyrotoxicosis. Horm. Res. 26: 158, 1987.
Trip M.D., Wiersinga W., Plomp T.A. Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism. Am. J. Med. 91: 507, 1991.
Martino E., Aghini-Lombardi L., Bartalena L., Grasso L., Loviselli A., Velluzzi F., Pinchera A., Braverman L.E. Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease. Arch. Intern. Med. 154: 2722, 1994.
Rey E., Bachrach L.K., Burrow G.N. Effects of amiodarone during pregnancy. Can. Med. Assoc. J. 136: 959, 1987.
Plomp A.T., Vulsma T., Vijlder J.J.M. Use of amiodarone during pregnancy. Eur. J. Obstet. Gynecol. Reprod. Biol. 43: 201, 1992.
Freedman M.D., Somberg J.C. Pharmacology and pharmacokinetics of amiodarone. J. Clin. Pharmacol. 31: 1061, 1991.
Harjai K.J., Licata A.A. Effects of amiodarone on thyroid function. Ann. Intern. Med. 126: 63, 1997.
Vrobel T.R., Miller P.E., Mostow N.D., Rakita L. A general overview of amiodarone toxicity: its prevention, detection, and management. Prog. Cardiovasc. Dis. 31: 393, 1989.
Rovet J.F., Ehrlich R.M., Sorbara D.L. Neurodevelopment in infants and preschool children with congenital hypothyroidism: etiological and treatment factors affecting outcome. J. Pediatr. Psychol. 17: 187, 1992.
Rovet J.F., Ehrlich R.M., Sorbara D.L. Intellectual outcome in children with fetal hypothyroidism. J. Pediatr. 110: 700, 1987.
Matsumura L.K., Born D., Kunii I.S., Franco D.B., Maciel R.M.B. Outcome of thyroid function in newborns from mothers treated with amiodarone. Thyroid 2: 279, 1992
Flanagan R.J., Storey G.C.A., Holt D.W. Rapid high-performance liquid Chromatographic method for the measurement of amiodarone in blood plasma or serum at the concentrations attained during therapy. J. Chromatogr. 187: 391, 1980.
Frankerburg W.K., Dodds J.B. Denver Developmental Screening Test. J. Pediatr. 71: 181, 1967.
Wechsler D. Wechsler Preschool and Primary Scale of Intelligence. Ed. Psychological Corporation, New York, 1967. (Italian edition, translated and adapted by permission in 1981 by S. Orsini, Organizzazioni Speciali, Firenze).
Decatte L., Dewolf D., Smitz J., Bougatef A., Deschepper J., Foulon W. Fetal hypothyroidism as a complication of amiodarone treatment for persistent fetal supraventricular tachycardia. Prenat. Diagn. 14: 762, 1994.
Darwiche A., Vanlieferinghen P., Lemery D., Paire M., Lusson J.R. Amiodarone et tachicardie supraventriculaire foetal. A propos d’un cas avec hypothyroïdie néonatale. Arch. Fr. Pediatr. 49: 729, 1992.
Ovadia M., Brito M., Hoyer G.L., Marcus F.I. Human experience with amiodarone in the embryonic period. Am. J. Cardiol. 73: 316, 1994.
Foster C.J. Amiodarone in pregnancy. Am. J. Cardiol. 74: 307, 1994.
Widerhorn J., Bhandari A.K., Bughi S., Rahimtoola S.H., Elkayam U. Fetal and neonatal adverse effects profile of amiodarone treatment during pregnancy. Am. Heart J. 1229: 1162, 1991.
Magee L.A., Dawnar E., Sermer M., Boulton B.C., Allen L.C., Koren G. Pregnancy outcome after gestational exposure to amiodarone in Canada. Am. J. Obstet. Gynecol. 172: 1307, 1995.
Nademanee K., Piwonka R.W., Singh B.N., Hershman J.M. Amiodarone and thryoid function. Prog. Cardiovasc. Dis. 31: 427, 1989.
Gill J., Heel R.C., Fitton A. Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 43: 69, 1992.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grosso, S., Berardi, R., Cioni, M. et al. Transient neonatal hypothyroidism after gestational exposure to amiodarone: A follow-up of two cases. J Endocrinol Invest 21, 699–702 (1998). https://doi.org/10.1007/BF03350801
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03350801